Lenor 2.5 mg (Tablet)

Indications

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
• First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer
• Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status
• Pre-operative therapy in postmenopausal women with localized hormone receptor positive breast cancer

Pharmacology

• Potent and highly specific nonsteroidal aromatase inhibitor
• Reduction of estrogen biosynthesis in all tissues
• Suppression of estrogen biosynthesis in peripheral and malignant tissues
• Suppression of serum oestrone and oestradiol by 75-78%
• Plasma protein binding of letrozole is approximately 60%

Dosage & Administration

• Recommended dose: 2.5 mg once daily
• Treatment duration: 5 years in adjutant and extended adjutant setting
• No dose adjustment for elderly patients
• No dosage adjustment required for patients with hepatic impairment or renal impairment

Interaction

• Co-administration with cimetidine and warfarin

Contraindications

• Known or suspected hypersensitivity to letrozole or other aromatase inhibitors
• Contraindicated during pregnancy, lactation, and in pre-menopausal women
• Contraindicated in severe hepatic dysfunction

Side Effects

• Common: Hot flushes, increased level of cholesterol, fatigue, gastrointestinal disorders
• Rare: Nervous disorders, eye disorders, skin disorders, weight decrease, urinary tract infection

Pregnancy & Lactation

• Teratogenicity and maternal toxicity in pregnant rats
• Not recommended for use in pregnant or nursing women

Precautions & Warnings

• No dosage adjustment for breast cancer patients with moderate hepatic dysfunction
• No dose adjustment necessary for renal impairment (calculated creatinine clearance: 20 to 50 ml/min)
• Caution recommended for patients with fatigue and dizziness

Overdose Effects

• No clinical experience of overdosage
• No specific antidote
• Dialysis may be helpful

Therapeutic Class

• Hormonal Chemotherapy

Storage Conditions

• Keep below 30°C temperature, away from light & moisture
• Keep out of the reach of children

Related Brands

• Femara 2.5 mg (Tablet) - novartis-bangladesh-ltd